Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

A randomized, controlled trial of GH supplementation to adult height in girls with short stature due to Turner syndrome was conducted in Canada.

The researchers report results in subjects who completed the protocol and subjects who participated in follow-up.

Who Took Part

By PubMed's age tags, the people studied were teenagers, women only.

Both cohorts received standardized sex steroid replacement starting at a chronological age of 13 yr.

Subjects were followed until protocol completion, defined as height velocity less than 2 cm/yr and bone age 14 yr or greater.

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

What Was Measured

The subject headings attached to it are Body Height, Chromosomes, Human, Y, Human Growth Hormone, Karyotyping, Phenotype, Reproducibility of Results and Turner Syndrome.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.